Background: The p53 gene (also known as TP53) may be the most common genetic target involved in the malignant transformation of human cells. Direct sequence analysis has demonstrated that alteration of this gene occurs in approximately 45% of head and neck squamous cell carcinomas. The consequences of p53 mutations in these cancers with respect to tumor behavior and patient survival have not been rigorously determined. Purpose: We evaluated the implications of p53 mutations in relation to the control of locoregional disease and overall survival following radiation therapy. Methods: Data from 110 consecutive patients with invasive disease who were treated with primary radiation therapy (given with curative intent) or with adjuvant radiation therapy (following complete surgical extirpation of gross disease) were included in the analysis. A 1.8-kilobase fragment of the p53 gene encompassing exons 5-9 was amplified from the DNA of stored (frozen) tumor specimens; the amplified DNA was cloned and sequenced by use of standard techniques. Overall survival and locoregional disease-free survival after the completion of radiation therapy were estimated by the Kaplan-Meier method; survival comparisons were made by use of the logrank test or proportional hazards regression models. Reported P
Clinical staging often fails to predict the response of individual tumors to treatment as well as the eventual outcome of many patients with head and neck squamous cell carcinoma (HNSCC). Currently, treatment options including radiation therapy, surgery, and chemotherapy are selected on the basis of stage and site of disease. Regardless of treatment method, some patients do well and others do not. Better markers for the biologic behavior of HNSCC are needed to help select therapy.
The delineation of specific genetic events leading to cancer development and progression should identify new molecular markers with prognostic value for the management of disease. The p53 gene (also known as TP53) may be the most common specific genetic target involved in human cell malignant transformation (/) . Direct sequence analysis has demonstrated that alteration of the p53 gene occurs in approximately 45% of HNSCCs (2) (3) (4) . The consequences of p53 gene mutations with respect to tumor behavior and patient survival in HNSCC have not been rigorously determined.
The absence of functional p53 protein has been linked to radiation resistance in animal models and in tissue culture. Studies (5, 6) indicate that p53 is necessary for apoptosis (programmed cell death), which occurs after DNA damage due to treatment with ionizing radiation and some chemotherapeutic agents. In the absence of functional p53 protein, a damaged malignant cell can continue to replicate, perhaps perpetuating further genetic alterations, rather than succumbing to antineoplastic therapy.
A number of investigators have attempted to derive prognostic information from immunohistochemical (IHC) studies assessing p53 protein overexpression as an indicator of genetic alteration. Wildtype p53 protein has a very short half-life, resulting in an absence of histochemical staining of normal cells with antibodies directed against p53 under most circumstances. Point mutation often causes a conformational change in the protein, resulting in a prolonged half-life and positive IHC staining (7, 8) . Data have been presented supporting the contentions that overexpression of p53 protein is associated with improved survival, no change in survival, and poor prognosis in patients with squamous cell carcinoma of the upper aerodigestive tract (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) . Attempts have also been made to associate p53 protein expression with responses to radiation therapy and chemotherapy
(2021).
A variety of factors may account for the ambiguity of results of clinical studies based on p53 protein immunostaining. Many of the studies involved small numbers of patients who were evaluated retrospectively, and they did not use timeto-event statistical methods. In addition, IHC detection of p53 protein overexpression and p53 gene alteration do not always correspond. Investigators must set an arbitrary threshold of staining that will be used to indicate p53 alteration. The choice of the threshold has a profound effect on the percentage of tumors judged to have p53 mutations (20%-80% in some series). There are a number of reasons for false-positive and false-negative results when using IHC staining to detect genetic changes (7, 82223 )-Nearly one third of all mutations in the p53 gene result in a failure of the cell to accumulate p53 protein (24) . IHC screening would score these as nonmutated tumors. In other cases, normal p53 protein may be bound and stabilized by proteins such as the adenovirus T antigen or the mdm2 protein, resulting in positive immunostaining and a false-positive result in IHC scoring (8) . In fact, in one study (18) , the agreement between IHC staining of p53 protein and direct gene sequencing to detect p53 mutations in HNSCC was only about 70%. Similarly, an analysis of p53 status in a large series of breast carcinoma specimens by use of both direct sequencing and IHC staining showed a 33% false-negative frequency and a 30% false-positive frequency for IHC detection of gene mutations (25) .
To date, there are no published reports correlating actual p53 gene mutation and clinical outcome in a large series of patients with HNSCC. The usual practice of sequencing exons 5-9 may miss 5%-10% of the p53 mutations present in the population (24) . However, direct sequencing remains the most reliable method for determining the presence of p53 gene mutations. To rigorously test the effect of p53 gene alteration on prognosis in HNSCC, we used sequence analysis to identify mutations in a large number of tumors. Patient outcome was tabulated and evaluated in relation to p53 mutation status and standard clinical parameters.
Methods

Patients
Consecutive patients from the Johns Hopkins Medical Institutions who were diagnosed with invasive HNSCC and were treated with radiation therapy as a primary or an adjuvant method were entered in the study at the time of biopsy or surgical resection. Patients who were referred after local excision with positive margins or after the initiation of chemotherapy or radiation therapy were included if the original date of diagnosis was within 3 months of study entry. All subjects were treated with aggressive therapy with curative intent, excluding those who refused treatment or those who initially presented with distant metastases. Clinical data were collected from the Johns Hopkins otolaryngology cancer registry, hospital charts, and interviews with the patients and/or treating physician. Outcome data were updated at 6-month intervals. All subjects provided written informed consent for participation in the study. The study was approved by the Joint Committee of Clinical Investigation of the Johns Hopkins Medical Institutions.
The data recorded for each patient included age, sex, the tumor-node-metastasis (TNM) stage (American Joint Committee on Cancer stages I-IV) (26), site and pathologic grade of the neoplasm, treatment method, and outcome (date of most recent follow-up, recurrence site and date, and cause and date of death). One hundred ten patients were included in the analysis.
Treatment
The molecular analysis of p53 status was performed retrospectively and treatment was not dictated by the study design. All patients received therapy chosen on the basis of clinical stage and site of disease according to the standard practice of the multidisciplinary head and neck oncology group. The diagnostic work-up and surgery for each case patient was performed at The Johns Hopkins Hospital or one of its affiliates. Radiation therapy was performed at The Johns Hopkins Oncology Center in the majority of cases: however, a number of patients received radiation therapy at other regional . facilities. Radiation therapy was given either as the primary treatment method in an effort to cure disease without surgery (Prim XRT) or as adjuvant postoperative therapy following complete surgical extirpation of gross disease (Adj XRT). Individuals in the Prim XRT group who had tumor recurrence after radiation therapy were treated with surgical salvage in many instances. In general, subjects treated with primary radiation therapy received 66-72 Gy to the primary site and first-echelon lymph nodes and 50 Gy to the remainder of the ipsilateral neck. Only two Prim XRT patients received less than 66 Gy. One patient received 60 Gy for a Tl vocal cord lesion and the other had no response after 57 Gy to a T4 lesion of the oral cavity when treatment was discontinued. Patients treated with primary surgery and postoperative radiation therapy began radiation treatment within 4-6 weeks of surgery, receiving 60-70 Gy to the primary site and involved neck regions.
Fifteen individuals also received neoadjuvant or concurrent platinum-based chemotherapy. Thirteen Prim XRT patients had concurrent (seven patients) or sequential (six patients) chemotherapy, while two Adj XRT patients had chemotherapy before or after surgery and postoperative radiation therapy.
Molecular Analysis
Samples of the invasive tumors were collected at biopsy or resection and were immediately frozen in liquid nitrogen. The frozen specimens were embedded in OCT (Tissue Tek, Elkhart, IN). Two 5-|im thick sections were taken for hematoxylin-eosin staining and examined by light microscopy. Microdissection of the tissue was performed to select regions with a high proportion (>50%) of neoplastic cells. Additionally, two sections were taken from the middle and deep portions of the neoplasm during sample processing and stained to ensure that the entire specimen was suitable for analysis. Between 50 and 100 12-um thick sections of tumor were digested overnight at 48 "C in 2 mL of a solution of sodium dodecyl sulfate (1%) and proteinase K (0.5 mg/mL), followed by extraction with buffered phenol-chloroform (three parts phenolAwo parts TEP buffer [500 nuW Tris, 20 mM EDTA, 10 mM NaCI; pH 9.0]/four parts chloroform) and precipitation of the DNA with ethanol as previously described (27) . Multiple colonies from each transformation were pooled separately, plasmid DNA was extracted, and double-stranded DNA (protein-coding regions and exon-intron boundaries) was sequenced by use of the dideoxy method, [a-PJdeoxyadenosine triphosphate (Dupont NEN; Boston, MA), and Sequenase (United States Biochemical Corp.; Cleveland, OH). The sequencing reaction products were then separated by electrophoresis in 8 M urea/6% polyacrylamide gels, which were fixed and exposed to x-ray film overnight at room temperature. The assay results were confirmed with repeated amplification, cloning, and sequencing of each tumor DNA.
Statistical Analysis
The two major statistical end points of this study were overall survival and time to diagnosis of treatment failure (disease-free survival) as documented by biopsy. The completion of primary or postoperative radiation therapy marked the beginning of all time-to-event measurements. Prim XRT subjects were considered to have had a complete response to therapy ("responders") if no biopsy documenting persistent tumor was obtained during the first 3 months after the completion of treatment. Eventtime distributions for these end points were estimated by use of the Kaplan-Meier method (29) and compared by use of either the logrank statistic (30) or proportional hazards regression models (31) . The simultaneous effect of two or more factors was studied using a multivariate proportional hazards model. Covanates that were marginally significant (P<. 19) in univariate analysis were entered in the multivariate regression model, and nonsignificant effects were removed in a stepwise fashion. Disease-specific survival (deaths from other causes censored) was assessed as a secondary end point. Factors tested for prognostic value included the stage and site of disease, the presence or absence of cervical lymph node metastasis, the degree of differentiation of the tumor, patient age, sex, and p53 status. Age was considered as both a continuous and a categorical variable. Two categorical age-grouping schemes were tested: 1) comparing individuals under 65 years of age with those over 65 years of age; and 2) comparing individuals under 55 years of age, those 55-70 years of age, and those over 70 years of age. To test for the effect of disease site, tumors of the oral cavity and hypopharynx, commonly considered to be associated with a poor prognosis, were grouped and compared with tumors at all other sites. The effect of stage was analyzed by grouping patients with stage I or II disease and comparing them with those with stage III or IV disease. All P values reported are two-sided. Cross-tabulations for associations between p53 status and clinical parameters were analyzed using chi-squared or Fisher's exact tests when appropriate. Computations were performed using SAS (32) or EGRET (33) statistical programs.
Results
Patient Characteristics
One hundred ten patients with invasive HNSCC were entered in the study. Patient characteristics are shown in Table   1 .
Molecular Analysis
Forty-eight (44%) of the 110 tumors had p53 mutations. The p53 gene in one tumor had tandem alterations and one patient had two separate tumors, each with a distinct p53 mutation, resulting in a total of 50 genetic mutations in our patient population. The most common p53 mutations for the total patient population were G:C -» A:T, G:C -> T:A, and A:T -> G:C changes. There is substantial (80%) overlap of this series with a group of 144 tumors for which the detailed spectrum of p53 mutations has been reported (J).
Ten of the tumors had p53 mutations that involved splice site alterations, frameshifts, deletions, or premature stop codons. These changes would produce either truncated or no p53 protein and would not be detected by IHC evaluation.
Clinical Outcome
The follow-up period ranged from 12 to 55 months. The overall median survival time was 41 months. The mean length of follow-up was identical for patients with tumors that either had or lacked p53 mutation.
Overall survival. A total of 43 patients died during the follow-up period ( Table  2) . No relationship was found between (37) for further description. §NP = nasopharynx; OC = oral cavity; OP = oropharynx; HP = hypopharynx; LA = larynx; UP = unknown primary.
UPrim XRT = primary radiation therapy, Adj XRT = adjuvant radiation therapy. overall survival and p53 mutation status ( Fig. 1, A ; Table 3 ). In contrast, stage of disease was a strong predictor of overall survival (Table 3) . Regional lymph node involvement also increased the risk for this end point. In a multivariate model, p53 status remained nonsignificant and stage remained a strong prognostic factor (data not shown). The histologic degree of tumor differentiation, the primary tumor site, patient age, and sex were not predictors of overall survival. The overall survival and diseasespecific survival end points were fairly similar, with 77% (33 of 43) of all deaths being disease related (Table 2 ). However, eight of the 10 deaths due to other causes occurred in the p53 wild-type group. with head and neck squamous cell carcinoma categorized according to p53 mutation status. Survival curves were generated by use of the Kaplan-Meier method. Representative 95% confidence intervals at two time points are provided for disease-free survival (arrows). The numbers of patients at risk at specific time points are shown below both sets of curves. .84
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Hence, although p53 status was likewise not a strong predictor of disease-specific survival (censoring death due to causes other than cancer), the results suggest that mutation may have slightly increased the risk of death due to HNSCC (Table 3) . Locoregional disease-free survival. A total of 39 patients had locoregional persistent or recurrent disease at some time during the follow-up period, including nearly half (23 of 48) of the patients whose tumors had p53 mutations (Table   2 ). There was no significant difference in the frequency of initial response to radiation therapy for tumors with and without p53 mutation in the Prim XRT group (Fisher's exact test; P = . 16). However, in univariate analysis, the time to locoregional recurrence for the entire population varied significantly with p53 status, lymph node status, and treatment group. Treatment of rumors with mutated p53 genes was two times as likely to fail locally (Table 3 ; Fig. 1, B) . Patients in the Prim XRT group were more likely to recur locally than those in the Adj XRT group. Nodal disease was a strong univariate predictor for this end point as well. Each of these factors remained significant in the multivariate regression analysis (Table 3) .
In the Adj XRT group, the effect of involved surgical margins and extracapsular spread of tumor out of cervical lymph nodes was considered. These were not significant predictors of locoregional recurrence in the univariate analysis and did not eliminate the effect of p53 mutation status in the multivariate regression.
Chemotherapy. Nearly half (seven of 15) of the tumors treated with chemotherapy had a p53 mutation. This group is too small to assess the contribution of chemotherapy to disease control and outcome or associations between p53 status and the efficacy of chemotherapy. Discussion p53 protein has been shown to play a role in cell cycle control and the apoptotic response to radiation and other causes of cell damage (34) . These factors have led investigators to postulate that the p53 status of tumors may be relevant to clinical outcome.
In an effort to address the question of the clinical importance of p53 mutation in HNSCC definitively, we used DNA sequencing to identify p53 gene alterations in a large group of tumors collected consecutively at the beginning of treatment. With more than 2 years of follow-up, the prognostic implication of this genetic alteration was assessed. The study failed to demonstrate a relationship between p53 mutation status and overall survival. Regional lymph node status and primary tumor stage, highly related parameters, were both prognostic for overall survival. Mutations in the p53 gene were, however, associated with a higher risk for locoregional treatment failure and a shorter disease-free interval after radiation therapy. This relationship was independent of other clinical factors.
An unexpected finding was the higher risk for recurrence in the Prim XRT group in relation to the Adj XRT group. This result may be due to the superior combined extirpative effects of multimodality therapy. Alternatively, it could reflect a bias introduced by treatment selection. However, half (21 of 42) of the patients treated with radiation therapy alone had early lesions (Tl-2). Only four of these individuals, divided equally between the mutant and wild-type groups, had disease recurrence. Twelve other patients had advanced but resectable lesions treated in organ-preservation regimens. Eight of these individuals had locoregional recurrence and were again divided equally by mutation status. Two Prim XRT patients had nasopharyngeal primary tumors, leaving seven who had advanced (marginally resectable) disease treated with radiation therapy alone. It is worthwhile to note again that the proportion of tumors with p53 mutations did not vary with treatment group or stage and that p53 status was found to be an independent predictor of locoregional recurrence in multivariate regression.
The association of p53 mutation with locoregional recurrence but not decreased survival might be explained by a variety of factors, such as differences in the frequencies of distant metastasis, salvage surgery, and death due to unrelated causes. Distant metastasis and surgical salvage affected roughly proportional numbers in each p53 group (Table 2) ; however, most of the deaths unrelated to cancer occurred in patients with p53 wild-type tumors. This is reflected in the fact that p53 status was slightly more predictive of disease-specific survival (death by unrelated cause censored) than of overall survival. Another explanation for the disparity between overall survival and locoregional disease-free survival is the limitation of precision possible in the analysis of the data. Indeed, the upper confidence limit of the estimated hazard ratio for disease-specific death in patients with p53-mutated tumors is 3.4. It is possible that p53 status might be shown to correspond to overall or disease-specific survival in a larger population, despite the equivocal results of this analysis.
Explanations can also be offered at the molecular level for the failure of p53 status to predict outcome more strongly in HNSCC. An accumulation of seven or more genetic alterations are probably required for the complete malignant transformation of an oral epithelial cell (35) . A more complete analysis of the spectrum of genetic changes will be needed to identify useful prognostic markers for HNSCC. In addition, mechanisms of radiation-induced tumor killing that are independent of the p53 apoptotic mechanism may account for the effective treatment of some mutated tumors.
Drawing clinical implications from the difference in locoregional disease control seen in this study is premature. If the data presented here are confirmed in large, prospectively defined cohorts after uniform treatment, then several applications may be suggested. Tumors resected with "close" margins may be treated best by re-excision prior to radiation therapy if the p53 gene is mutated. Prophylactic neck dissections for NQ (no regional lymph node metastasis) necks may be employed for patients with p53 mutations, relying more readily on radiation alone for patients with tumors with wildtype genes. Chemotherapeutic agents such as paclitaxel (Taxol) that work through pathways independent of p53-mediated apoptosis may be selected for combined-treatment regimens for tumors with p53 mutations (36).
In conclusion, the largest series of HNSCCs collected to date has been analyzed by direct gene sequencing in an attempt to determine the clinical significance of p53 gene mutation. Although no relationship was found between p53 mutation in patients with HNSCC and overall survival, mutation was associated with an increased risk of locoregional recurrence after treatment that included radiation therapy.
Background: Pancreatic cancer is a common cause of mortality in the United States, with an estimated 27 800 people dying of the disease in this country in 1996. Epidemiologic studies have suggested that Western diets containing high fat, high protein, and low calcium contents are associated with increased incidence of pancreatic cancer. Purpose: We investigated whether a Western-style diet containing increased fat content and decreased calcium and vitamin D contents would induce epithelial cell hyperproliferation (excess cell duplication) or hyperplasia (excess cell accumulation) in the pancreas, as was previously demonstrated in the colon and mammary gland. Methods: C57BL/6J mice at 4 weeks of age were randomly assigned to one of two groups of 14 mice each. One group received the control diet ad libitum, and the other group was given the Western-style diet ad libitum. After 6, 9, and 15 weeks on the diet, four or five mice per group were infused with 5-bromo-2'-deoxyuridine (BrdU) for 72 hours by use of subcutaneously implanted Alzet osmotic pumps. The mice were then killed, and the pancreas of each mouse was removed. In the exocrine pancreas with ductal secretion, the duct system (including interlobular and intralobular ducts and centroacinar [i.e., centroductular] cells) and acini were measured both histopathologically and immunohistochemically (BrdU) and were analyzed without knowledge of the source of the specimens. Two-way analysis of variance was carried out. All P values were generated from two-sided tests for statistical significance. Results: The number of pancreatic ducts (interlobular, intralobular, and centroacinar-cancer-prone regions in certain rodent models and in humans) and acini per mouse in the Western-style diet group was similar to that in the control diet group during the entire feeding period (P = .76, .32, .93, and .42, respectively). Statistically significant higher BrdU-labeling indices of the ductal interlobular and intralobular epithelial cells were seen in mice fed the Western-style diet than in mice fed the control diet during the entire observation period (P = .014 and .016, respectively). There was no statistically significant difference (P = Carcinoma of the pancreas is a common cause of mortality in Western countries. It has been estimated that approximately 26 300 new patients with pancreatic cancer will be detected and 27 800 people will die of this disease in the United States in 1996 (/) . Obviously, carcinoma of the pancreas remains one of the most important human cancers because reliable methods of early disease detection and effective treatment are lacking (2) . Moreover, several dietary constituents that have been implicated as causative factors include high dietary fat and protein intake (3) (4) (5) and low calcium intake (6) .
Previous studies from our laboratory (7) (8) (9) (10) See "Notes" section following "References."
